Funding profile · Protein design tools

Medium Biosciences

The public record shows one funded round: $125K from Y Combinator in September 2021. Later rounds and six named investors appear on databases without amounts, and no SEC Form D was found.

$125KY Combinator investment, Sep 2021, per PitchBook and Tracxn
0SEC Form D filings found for the company
6Investors listed by PitchBook, no amounts
$900K2024 revenue, third party estimate, unconfirmed

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Sep 2, 2021 Accelerator $125K Y Combinator Independent database
Nov 2, 2021 Early stage VC Not disclosed Not listed by round Independent database
Nov 1, 2022 Early stage VC Not disclosed Not listed by round Independent database
Total Per CB Insights $130K Y Combinator, E14 Fund, AIX Ventures, SBXi Differs by $5K

What the filings show

No Form D on file for Medium Biosciences

Search
Records match of SEC Form D and EDGAR mentions returned zero results
Near miss
Droplet Biosciences, Inc., CIK 0001847243, filed a Form D on May 27, 2021 for $5,348,980 sold to 30 investors. It is a Massachusetts company with different officers and is not related
Meaning
Any priced round was either not filed, filed under another entity name, or filed outside the search window

Reading the filings

  1. The only dollar figure is an accelerator check.$125K is the standard size of a Y Combinator deal at the time. PitchBook and Tracxn agree on it. CB Insights shows $130K, a $5K gap that no source explains. Getlatka shows $0 in funding.
  2. Investor list outruns the amounts.PitchBook counts 6 investors: AIX Ventures, E14 Fund, Village Global, SBXi, one individual angel and Y Combinator. Two follow on rounds have no size, so the money behind five of the six is unknown.
  3. No Form D means no verified round.A US company selling equity to accredited investors under Regulation D normally files one within 15 days of the first sale. None was found. Small SAFE rounds sometimes go unfiled or unindexed under the company name.
  4. Revenue and size do not line up.Getlatka estimates $900K revenue in June 2024 with 6 staff, which would be $150K per head. PitchBook says 3 employees and Employbl says 2. Against $125K raised, revenue of that size would mean customers paid for most of the company’s runway. The estimate is unconfirmed.
  5. Headquarters differ.YC, PitchBook and Getlatka say San Francisco. CB Insights and LifeScienceHistory say Boston. A state of incorporation or principal place of business would come from a Form D, and there is none.

Commercial signals

Signal Detail Source type
Customers 10+ across industry and academia, none named Company-stated
Projects 25+ completed projects, 20+ unique proteins engineered Company-stated
Competition Second place in the Protein Engineering Tournament, and listed as an organizer Independent
Publication Tournament results paper, Proteins, Nov 2025, both founders among the authors Public record
Accelerator Y Combinator Summer 2021 Independent
Federal grants None tied to the company Not found

What to watch

  • A Form D under Medium Biosciences, Inc. or a related vehicle, which would show the first priced round.
  • Named customers that would turn the 10+ count into something checkable.
  • Whether database totals converge on one figure for money raised.

The Medium Biosciences story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Synapsica Healthcare: Shared investor: Independent Fund. A Bengaluru company that tried to write the spine report for the radiologist
  • Culture Biosciences: Shared investor: E14 Fund. A cloud lab that ran other companies’ fermentation for them, now selling the bioreactor itself through Cytiva
  • Volta Labs: Shared investor: E14 Fund. An MIT spinout that prepares DNA for sequencing by walking droplets across a circuit board instead of pipetting them between plates
  • InVision Medical Technology: Shared investor: Independent Fund. Two FDA-cleared models that read heart ultrasounds already being performed, built by the lab that published the underlying papers first

Sources

  1. Public recordSEC EDGAR Form D records match, none for Medium BiosciencesSEC EDGAR · Sep 2026
  2. Public recordDroplet Biosciences, Inc. Form D, CIK 0001847243SEC EDGAR · May 27, 2021
  3. Public recordResults of the Protein Engineering Tournament, PMID 40546234PubMed, Proteins · Nov 2025
  4. IndependentMedium Biosciences 2026 company profilePitchBook · Aug 2026
  5. IndependentMedium Biosciences funding rounds and investorsTracxn · 2024
  6. IndependentMedium Biosciences products, financials and employeesCB Insights · 2026
  7. IndependentMedium Biosciences revenue estimateGetlatka · Sep 2026
  8. IndependentMedium Biosciences profile, jobs and fundingEmploybl · 2022
  9. IndependentInnovating Through Collaboration: The Protein Engineering Tournament’s Impact on Computational DesignCBIRT · Nov 21, 2024
  10. CompanyCustom affinity reagents, designed for your target and applicationMedium Biosciences website, Internet Archive · 2026
  11. CompanyMedium Biosciences: AI-designed Affinity ReagentsY Combinator · Jul 2026

Compiled from SEC and other public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date. Healthcare Venture Capital Fund holds no position in Medium Biosciences. This page is not an offer to sell or a recommendation to buy any security.